Inadequate activation of the immune system against malignant cells. Overcoming this suppression enables more effective therapeutic targeting of cancers.

Dysregulated kinase signaling leads to malignant growth and inflammatory tissue damage. Inhibiting these pathways prevents disease progression and treatment resistance.

Primary oncogenic drivers develop secondary mutations that render standard reversible inhibitors ineffective. Overcoming these mutations restores therapeutic efficacy in resistant cell populations.